

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. B45201	SERIAL NO. 10/088,632
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>		APPLICANT D'Hondt, <i>et al.</i>	
		FILING DATE 30 July 2002	GROUP 1648

#### U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

#### FOREIGN PATENT DOCUMENTS

MH	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	EP 0113 665	18-Jul-1984	EP				
	WO 95/22989	31-Aug-1995	PCT				

#### OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	Boger, <i>et al.</i> , "Subcutaneous and Intradermal Vaccination with Asian Influenza Vaccine," <i>J.A.M.A.</i> , 1957, 165(13):1687-1689.
	Couch, <i>et al.</i> , "Improvement of Inactivated Influenza Virus Vaccines," <i>The Journal of Infectious Diseases</i> , 1997, 176:S38-S44.
	Hehme, N.W., "GSK's Pandemic Flu Vaccine Project: Evaluation of H2N2 and H9N2 Candidate Vaccines" GlaxoSmithKline Biologicals, <i>Who Meeting on Development and Evaluation of Influenza Pandemic Vaccines</i> , Geneva, 2005, pages 1-20.
	Kistner, <i>et al.</i> , "Development of a Mammalian Cell (Vero) Derived Candidate Influenza Virus Vaccine," <i>Vaccine</i> , 1998, 16(9/10):960-968.
	Kistner, <i>et al.</i> , "Development of a Vero Cell-Derived Influenza Whole Virus Vaccine," <i>Developments in Biological Standardization</i> , 1999, 98:101-110.
	La Montagne, <i>et al.</i> , "Summary of Clinical Trials of Inactivated Influenza Vaccine," <i>Reviews of Infectious Diseases</i> , 1983, 5(4):723-736.
	Lin, <i>et al.</i> , "Safety and Immunogenicity of an Inactivated Adjuvanted Whole-Virion Influenza A (H5N1) Vaccine: A Phase I Randomised Controlled Trial," <i>The Lancet</i> , 2006, 368:991-997.
	Merten, <i>et al.</i> , "Production of Influenza Virus in Cell Cultures for Vaccine Preparation," <i>Advances in Experimental Medicine and Biology</i> , 1996, 397:141-151.
	Offit, <i>et al.</i> , "Addressing Parents' Concerns: Do Vaccines Contain Harmful Preservatives, Adjuvants, Additives, or Residuals?" <i>Pediatrics</i> , 2003, 112(6):1394-1401.
	Rinella, <i>et al.</i> , "Effect of Anions on Model Aluminum-Adjuvant-Containing Vaccines," <i>Journal of Colloid and Interface Science</i> , 1995, 172:121-130.
	Seeber, <i>et al.</i> , "Predicting the Absorption of Proteins by Aluminum-Containing Adjuvants," <i>Vaccine</i> , 1991, 9:201-203.
	Shirodkar, <i>et al.</i> , "Aluminum Compounds Used as Adjuvants in Vaccines," <i>Pharmaceutical Research</i> , 1990, 7(12):1282-1288.

Serial No.: 10/088,632.  
Group Art Unit No.: 1648

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

MH		Stephenson, <i>et al.</i> , "Development of Vaccines Against Influenza H5," <i>The Lancet</i> , 2006, 6:458-460.
		Stephenson, I., "H5N1 Vaccines: How Prepared are we for a Pandemic?" <i>The Lancet</i> , 2006, 368:965-966.
		White, <i>et al.</i> , Characterization of Aluminum-Containing Adjuvants," <i>Developmental Biology</i> , 2000, 103:217-228.
↓		"Early Trial Show H5N1 Influenza Vaccine Safe and Effective in Humans at Low Doses," <i>The Lancet Press Release</i> , 2006.
EXAMINER		DATE CONSIDERED
/Michelle Horning/		02/01/2007
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

n:\ejh\applins\b cases\b45201\pto1449-3.doc